Vincristine
As of the edition of 20 October 2026, Vincristine is a small molecule: marketed, first approved in 1982 (US); acts on TUBB, TUBB1 and TUBB2A and 6 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Oncovin
- First approved
- 1 January 1982 (US)
- Approvals on record
- 8 in 5 regions
- Holder of the most recent approval
- Acrotech Biopharma; 4 holders in all
- Registered trials
- 922, 98 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Infections; Nervous system; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 50 | 23 | 10 | 4 |
| Phase 1 | 118 | 65 | 26 | 21 |
| Phase 2 | 468 | 238 | 111 | 59 |
| Phase 3 | 256 | 136 | 58 | 14 |
| Phase 4 | 30 | 19 | 4 | 0 |
| All trials | 922 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 1996 to now |
| Acrotech Biopharma | Acquired holder and Lead sponsor of trials | 2001 to now |
| Eli Lilly | Applicant and Lead sponsor of trials | 2007 to now |
| Nippon Kayaku | Applicant |